A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough

被引：1
|
作者：
Santos, Raul D. [1 ,2 ]
Nasir, Khurram [3 ]
Shapiro, Michael D. [4 ]
机构：
[1] Univ Sao Paulo, Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil
[2] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil
[3] Houston Methodist DeBakey Heart & Vasc Ctr, Dept Cardiol, Div Cardiovasc Prevent & Wellness, Houston, TX USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Ctr Prevent Cardiovasc Dis, Sect Cardiovasc Med, Winston Salem, NC 27157 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 84卷 / 20期
基金：
美国国家卫生研究院;
关键词：
KEY WORDS LDL-C; lipoproteins; mixed hyperlipemia; nonfamilial hypercholesterolemia; PCSK9; recaticimab;
D O I：
10.1016/j.jacc.2024.09.019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2048 / 2050
页数：3
相关论文
共 50 条
  • [1] PCSK9 inhibition: the way forward in the treatment of dyslipidemia
    Robert M. Stoekenbroek
    John JP Kastelein
    Roeland Huijgen
    BMC Medicine, 13
  • [2] PCSK9 inhibition: the way forward in the treatment of dyslipidemia
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    Huijgen, Roeland
    BMC MEDICINE, 2015, 13
  • [3] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [4] Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury, Sharmistha Roy
    Rees, Alan
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (05) : 509 - 510
  • [5] PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (06) : 590 - 601
  • [6] PCSK9 inhibition in PAD
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2018, 15 (01) : 4 - 5
  • [7] PCSK9 inhibition in PAD
    Karina Huynh
    Nature Reviews Cardiology, 2018, 15 : 4 - 5
  • [8] The promises of PCSK9 inhibition
    Petrides, Francine
    Shearston, Kate
    Chatelais, Mathias
    Guilbaud, Florian
    Meilhac, Olivier
    Lambert, Gilles
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (04) : 307 - 312
  • [9] Update on PCSK9 inhibition
    Katzmann, Julius L.
    Custodis, Florian
    Schirmer, Stephan H.
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 196 - 203
  • [10] PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention Another Step Forward
    Alberts, Mark J.
    Thompson, Paul D.
    STROKE, 2020, 51 (05) : 1361 - 1362
12345